Skip to main content
MMedVellum
MCQsExamsAtlas
DashboardPricing
MMedVellum

The exam atlas that feels like a flagship product — evidence-graded topics and exam tools for MBBS and fellowship preparation. Built to scale to fifty specialties. Educational content only — not medical advice.

llms.txt·psychiatry LLM catalog · sitemap

Atlas

  • Specialty atlas
  • MBBS / Core medicine
  • Dermatology
  • ICU Fellowship (CICM)
  • Anaesthesia
  • Emergency Medicine
  • Psychiatry Fellowship

Study & account

  • MCQ practice
  • Practice alias
  • Exam tools
  • Dashboard
  • Pricing
  • Sign in

© 2026 MedVellum. For education only — not a substitute for clinical judgement.

Clinical Atlas Prestige · Evidence-first

Psych MEQs / SAQsChild and adolescent psychiatry — OCRD

Psych MEQs / SAQs · Child and adolescent psychiatry — OCRD

Childhood-onset OCD — ERP, POTS and SSRI monitoring (MEQ)

FRANZCP-style modified essay on paediatric OCD diagnosis, CY-BOCS, family accommodation, ERP, SSRI monitoring, and POTS evidence.

20 marks20 min
On this page & tools

Target exams

FRANZCPMRCPsychABPNMD-DNB

Target exams

FRANZCPMRCPsychABPNMD-DNB
Prompt
A 12-year-old girl is referred with two years of progressive contamination fears, prolonged handwashing until skin cracks, rewriting homework until letters look 'perfect', and nightly checking of door locks. She spends several hours daily on rituals. Parents answer dozens of reassurance questions and have stopped family outings. She is ashamed of intrusive thoughts that she might harm her baby brother 'by mistake'. Attendance has fallen and peers tease her about smelling of soap. No clear acute post-infectious onset. (i) State the working diagnosis with DSM-5-TR logic and key differentials including tic-related and PANDAS considerations. (ii) Outline assessment priorities including a named severity scale and family accommodation. (iii) Present a stepped management plan including psychoeducation, ERP structure, and when to use SSRI with agent examples, dose framework and monitoring. (iv) Summarise POTS and POTS II implications for combination/augmentation. (v) Outline school and risk counselling points. (20 marks)

Model answer

Reveal model answer

(i) Diagnosis and differentials. Working diagnosis: obsessive-compulsive disorder, childhood-onset, multi-dimensional (contamination/washing, symmetry/rewriting, checking) with marked time cost and impairment, good-to-fair insight suggested by shame/ego-dystonic tone of harm thoughts. Not primarily psychotic. Differentials: ASD routines (less fitting ego-dystonic anxiety here), complex tics (screen for tic-related specifier), GAD, illness anxiety, depression, body-focused OCRDs if relevant. PANDAS/PANS less likely with gradual multi-year course and no acute post-infectious story — mention concept without forcing work-up as default.[3][7]

(ii) Assessment. Multi-informant history of content, hours, avoidance, school impact, risk (self-harm, harm-obsessions distress, neglect of self-care). Inventory family accommodation (reassurance, participation, restricted outings).[6] Screen tics, ADHD, mood, ASD traits, substances, safeguarding/bullying. Use CY-BOCS for severity baseline and tracking.[4] Shared formulation with youth and carers.

(iii) Stepped management. Psychoeducation: OCD loop, not wilful; reduce accommodation as treatment target. First-line psychological: CBT with ERP — hierarchy, exposure without rituals (including mental reviewing and reassurance), homework, carer coaching; evidence supports CBT effect sizes in paediatric meta-analysis.[9][3] For this moderate–severe multi-hour presentation, discuss SSRI concurrent or sequential: e.g. sertraline start approximately 25 mg oral daily, titrate toward paediatric OCD ranges often up to about 50–200 mg/day; alternatives fluoxetine (e.g. 10 then 20 mg, titrate toward ~20–60 mg) with black-box suicidality/activation monitoring, early review, carer education. Adequate trial ~8–12 weeks at therapeutic dose. Verify local PI.[5][8][3]

(iv) POTS / POTS II. POTS: CBT and sertraline each beat placebo; combination particularly effective for severe illness — justifies combined pathway here.[1] POTS II: if partial SRI response, add/intensify CBT rather than medication management alone.[2] (Note POTS Jr if examiner asks about under-8s — family-based CBT.)[10]

(v) School and risk. Risk assess forbidden-harm thoughts (ego-dystonic vs intent), suicide/self-harm, skin breakdown, school refusal. School plan: gradual return, bathroom timing accommodations without enabling endless washing, anti-bullying, staff psychoeducation. Written crisis contacts; follow-up for ERP and medication titration.[3]

Common errors

  • Treating harm obsessions as imminent risk of violence without distinguishing ego-dystonic OCD.
  • Generic supportive therapy without naming ERP.
  • Ignoring family accommodation.
  • Declaring SSRI failure after days, or omitting black-box monitoring.
  • Routine PANDAS antibiotics for gradual OCD. [1][3][6][7]

Examiner notes

Full marks require DSM logic, CY-BOCS, accommodation, ERP structure, SSRI example with monitoring, and named POTS/POTS II implications. [1][2][4]

References

  1. [1]Pediatric OCD Treatment Study (POTS) Team Cognitive-behavior therapy, sertraline, and their combination for children and adolescents with obsessive-compulsive disorder: the Pediatric OCD Treatment Study (POTS) randomized controlled trial JAMA, 2004.PMID 15507582
  2. [2]Franklin ME, Sapyta J, Freeman JB, et al. Cognitive behavior therapy augmentation of pharmacotherapy in pediatric obsessive-compulsive disorder: the Pediatric OCD Treatment Study II (POTS II) randomized controlled trial JAMA, 2011.PMID 21934055
  3. [3]American Academy of Child and Adolescent Psychiatry Practice parameter for the assessment and treatment of children and adolescents with obsessive-compulsive disorder J Am Acad Child Adolesc Psychiatry, 2012.PMID 22176943
  4. [4]Scahill L, Riddle MA, McSwiggin-Hardin M, et al. Children's Yale-Brown Obsessive Compulsive Scale: reliability and validity J Am Acad Child Adolesc Psychiatry, 1997.PMID 9183141
  5. [5]March JS, Biederman J, Wolkow R, et al. Sertraline in children and adolescents with obsessive-compulsive disorder: a multicenter randomized controlled trial JAMA, 1998.PMID 9842950
  6. [6]Calvocoressi L, Lewis B, Harris M, et al. Family accommodation in obsessive-compulsive disorder Am J Psychiatry, 1995.PMID 7864273
  7. [7]Swedo SE, Leonard HL, Garvey M, et al. Pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections: clinical description of the first 50 cases Am J Psychiatry, 1998.PMID 9464208
  8. [8]Geller DA, Hoog SL, Heiligenstein JH, et al. Fluoxetine treatment for obsessive-compulsive disorder in children and adolescents: a placebo-controlled clinical trial J Am Acad Child Adolesc Psychiatry, 2001.PMID 11437015
  9. [9]Watson HJ, Rees CS Meta-analysis of randomized, controlled treatment trials for pediatric obsessive-compulsive disorder J Child Psychol Psychiatry, 2008.PMID 18400058
  10. [10]Freeman J, Sapyta J, Garcia A, et al. Family-based treatment of early childhood obsessive-compulsive disorder: the Pediatric Obsessive-Compulsive Disorder Treatment Study for Young Children (POTS Jr)—a randomized clinical trial JAMA Psychiatry, 2014.PMID 24759852